

Table S1 STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies

STROBE guidelines

| Section/topic | Item number | Recommendation | Page No |
|----------------------|-------------|--|---------|
| Title and abstract | 1 | Indicate the study’s design with a commonly used term in the title or the abstract Provide in the abstract an informative and balanced summary of what was done and what was found | 2-4 |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 6 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 6-7 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the manuscript | 7 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 7 |
| Participants | 6 | Cohort study - give the eligibility criteria, and the sources and methods of selection of participants; describe methods of follow-up Case-control study - give the eligibility criteria, and the sources and methods of case ascertainment and control selection; give the rationale for the choice of cases and controls Cross-sectional study - give the eligibility criteria, and the sources and methods of selection of participants Cohort study - for matched studies, give matching criteria and number of exposed and unexposed Case-control study - for matched studies, give matching criteria and the number of controls per case | 7 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers; give diagnostic criteria, if | 7-8 |

| STROBE guidelines | | | |
|------------------------------|-------------|---|---------|
| Section/topic | Item number | Recommendation | Page No |
| | | applicable | |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement); describe comparability of assessment methods if there is more than one group | 7-8 |
| Bias | 9 | Describe any efforts to address potential sources of bias | - |
| Study size | 10 | Explain how the study size was arrived at | 7 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses; if applicable, describe which groupings were chosen and why | 7 |
| Statistical methods | 12 | Describe all statistical methods, including those used to control for confounding Describe any methods used to examine subgroups and interactions Explain how missing data were addressed Cohort study - if applicable, explain how loss to follow-up was addressed Case-control study - if applicable, explain how matching of cases and controls was addressed Cross-sectional study - if applicable, describe analytical methods taking account of sampling strategy Describe any sensitivity analyses | 8-10 |
| Results | | | |
| Participants | 13* | Report numbers of individuals at each stage of study - e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed Give reasons for nonparticipation at each stage Consider use of a flow diagram | 10 |
| Descriptive data | 14* | Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders | 10 |

| STROBE guidelines | | | |
|-------------------|-------------|--|----------------|
| Section/topic | Item number | Recommendation | Page No |
| Outcome data | 15* | Indicate number of participants with missing data for each variable of interest | 11 |
| | | Cohort study - summarize follow-up time (e.g., average and total amount) | |
| | | Cohort study - report numbers of outcome events or summary measures over time | |
| Main results | 16 | Case-control study - report numbers in each exposure category, or summary measures of exposure | 11-12 |
| | | Cross-sectional study - report numbers of outcome events or summary measures | |
| | | Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval); make clear which confounders were adjusted for and why they were included | |
| Other analyses | 17 | Report category boundaries when continuous variables were categorized | Not applicable |
| Discussion | 18 | If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | |
| | | Report other analyses done - e.g., analyses of subgroups and interactions, and sensitivity analyses | |
| | | | |
| Key results | 19 | Summarize key results with reference to study objectives | 12 |
| Limitations | 20 | Discuss limitations of the study, taking into account sources of potential bias or imprecision; discuss both direction and magnitude of any potential bias | 14 |
| Interpretation | 21 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 12-14 |
| Generalizability | 22 | Discuss the generalizability (external validity) of the study results | 12-14 |
| Other information | | | |
| Funding | 22 | Give the source of funding and the role of | 15 |

| | | | |
|--|-------------|--|---------|
| STROBE guidelines | | | |
| Section/topic | Item number | Recommendation | Page No |
| | | the funders for the present study and, if applicable, for the original study on which the present article is based | |
| *Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies | | | |

Table S2 Scoring of different diseases in Charlson Comorbidity Index

| Scoring | Comorbidity |
|---------|--|
| 1 | Ischemic heart disease; congestive heart failure; peripheral vascular disease; cerebrovascular disease; dementia; chronic pulmonary disease; mild liver disease; diabetes without chronic complication |
| 2 | Diabetes with chronic complication; renal impairment; tumor without metastasis |
| 3 | Moderate or severe liver disease |
| 6 | Metastatic solid tumor; AIDS |

Abbreviate: AIDS, Acquired Immune Deficiency Syndrome

Table S3 Correlation coefficient of symptoms, functions, financial difficulties, characteristics and gQoL

| | Physical Function | Role Function | Emotional Function | Cognitive Function | Social Function | Fatigue | Nausea/vomiting | Pain | Dyspnea | Insomina | Appetite | Constipation | Diarrhea | Financial difficulties | gQoL | Age | CCI |
|------------------------|-------------------|---------------|--------------------|--------------------|-----------------|---------|-----------------|--------|---------|----------|----------|--------------|----------|------------------------|--------|-------|-------|
| Physical Function | 1.000 | | | | | | | | | | | | | | | | |
| Role Function | 0.680 | 1.000 | | | | | | | | | | | | | | | |
| Emotional Function | 0.282 | 0.324 | 1.000 | | | | | | | | | | | | | | |
| Cognitive Function | 0.352 | 0.417 | 0.486 | 1.000 | | | | | | | | | | | | | |
| Social Function | 0.491 | 0.564 | 0.380 | 0.429 | 1.000 | | | | | | | | | | | | |
| Fatigue | -0.688 | -0.709 | -0.524 | -0.512 | -0.722 | 1.000 | | | | | | | | | | | |
| Nausea vomiting | -0.322 | -0.301 | -0.348 | -0.165 | -0.247 | 0.430 | 1.000 | | | | | | | | | | |
| Pain | -0.488 | -0.536 | -0.368 | -0.368 | -0.469 | 0.607 | 0.343 | 1.000 | | | | | | | | | |
| Dyspnea | -0.368 | -0.491 | -0.285 | -0.385 | -0.351 | 0.542 | 0.313 | 0.458 | 1.000 | | | | | | | | |
| Insomina | -0.254 | -0.282 | -0.381 | -0.408 | -0.298 | 0.462 | 0.260 | 0.406 | 0.336 | 1.000 | | | | | | | |
| Appetite | -0.396 | -0.427 | -0.358 | -0.306 | -0.408 | 0.555 | 0.512 | 0.455 | 0.410 | 0.270 | 1.000 | | | | | | |
| Constipation | -0.287 | -0.324 | -0.252 | -0.165 | -0.213 | 0.347 | 0.351 | 0.357 | 0.308 | 0.254 | 0.415 | 1.000 | | | | | |
| Diarrhea | -0.213 | -0.188 | -0.166 | -0.116 | -0.188 | 0.290 | 0.327 | 0.220 | 0.301 | 0.212 | 0.305 | 0.184 | 1.000 | | | | |
| Financial difficulties | -0.310 | -0.340 | -0.230 | -0.285 | -0.467 | 0.434 | 0.277 | 0.308 | 0.304 | 0.140 | 0.273 | 0.214 | 0.285 | 1.000 | | | |
| gQoL | 0.329 | 0.469 | 0.331 | 0.364 | 0.397 | -0.513 | -0.265 | -0.407 | -0.404 | -0.302 | -0.379 | -0.283 | -0.213 | -0.336 | 1.000 | | |
| Age | -0.230 | -0.138 | 0.007 | -0.015 | -0.120 | 0.129 | -0.016 | 0.022 | 0.052 | -0.053 | 0.062 | 0.045 | 0.014 | 0.026 | -0.086 | 1.000 | |
| CCI | -0.264 | -0.240 | -0.070 | -0.138 | -0.225 | 0.308 | 0.220 | 0.202 | 0.238 | 0.099 | 0.288 | 0.170 | 0.257 | 0.277 | -0.277 | 0.123 | 1.000 |

Abbreviate: gQoL, Global health/quality of life; CCI, Charlson Comorbidity Index;

Table S4 Descriptive statistics of the items

| Item content | Expected influence | Predictability |
|------------------------|--------------------|----------------|
| Age | 0.048 | 0.965 |
| CCI | 0.382 | 0.901 |
| gQoL | 0.824 | 0.813 |
| Physical Function | 0.724 | 0.665 |
| Role Function | 1.052 | 0.625 |
| Emotional Function | 0.739 | 0.801 |
| Cognitive Function | 0.671 | 0.776 |
| Social Function | 0.873 | 0.669 |
| Fatigue | 1.617 | 0.450 |
| Nausea/vomiting | 0.656 | 0.793 |
| Pain | 0.783 | 0.736 |
| Dyspnea | 0.761 | 0.773 |
| Insomina | 0.556 | 0.815 |
| Appetite loss | 0.860 | 0.742 |
| Constipation | 0.503 | 0.872 |
| Diarrhea | 0.492 | 0.893 |
| Financial difficulties | 0.566 | 0.837 |

Abbreviate: CCI, Charlson Comorbidity Index; gQoL, Global health/quality of life

Table S5 Multiple linear analysis related to gQoL

| | Unstandardized | | Standardized | P-value | F | adj R ² |
|------------------------|-----------------------|-------|--------------|--------------|------|--------------------|
| | β (95%CI) | SE | β | | | |
| | | | | <0.001 | 22.4 | 0.329 |
| Role function | 0.131(0.042-0.220) | 0.045 | 0.161 | 0.004 | | |
| Emotional function | 0.068(-0.031-0.167) | 0.050 | 0.064 | 0.177 | | |
| Cognitive function | 0.070(-0.023-0.164) | 0.048 | 0.070 | 0.139 | | |
| Fatigue | -0.096(-0.224-0.033) | 0.065 | -0.102 | 0.144 | | |
| Pain | -0.046(-0.133-0.041) | 0.044 | -0.053 | 0.296 | | |
| Dyspnea | -0.078(-0.159-0.002) | 0.041 | -0.090 | 0.057 | | |
| Insomnia | -0.034(-0.091-0.022) | 0.029 | -0.054 | 0.232 | | |
| Appetite | -0.049(-0.128-0.030) | 0.040 | -0.059 | 0.223 | | |
| Constipation | -0.036(-0.104-0.032) | 0.035 | -0.044 | 0.303 | | |
| Financial difficulties | -0.076(-0.142--0.010) | 0.034 | -0.097 | 0.024 | | |
| CCI | -0.988(-1.749--0.227) | 0.387 | -0.104 | 0.011 | | |

Abbreviate: gQoL, Global health/quality of life; CCI, Charlson Comorbidity Index